Allogene Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Allogene Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
Allogene Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$71.8M, a 13.9% decline year-over-year.
Allogene Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$298M, a 12.2% increase year-over-year.
Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$328M, a 2.32% increase from 2022.
Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$336M, a 86.2% decline from 2021.
Allogene Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$180M, a 30.2% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$298M	-$71.8M	-$8.78M	-13.9%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-07
Q2 2024	-$289M	-$71.4M	+$9.11M	+11.3%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-07
Q1 2024	-$298M	-$69.5M	+$29.6M	+29.9%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-13
Q4 2023	-$328M	-$85.1M	+$11.3M	+11.7%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-14
Q3 2023	-$339M	-$63M	+$19.5M	+23.7%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-07
Q2 2023	-$359M	-$80.5M	-$3.92M	-5.12%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-07
Q1 2023	-$355M	-$99.1M	-$19.1M	-23.8%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-13
Q4 2022	-$336M	-$96.4M	-$98.1M	-5744%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-14
Q3 2022	-$237M	-$82.5M	-$4.84M	-6.23%	Jul 1, 2022	Sep 30, 2022	10-K	2024-03-14
Q2 2022	-$233M	-$76.6M	-$5.59M	-7.87%	Apr 1, 2022	Jun 30, 2022	10-K	2024-03-14
Q1 2022	-$227M	-$80M	-$46.8M	-141%	Jan 1, 2022	Mar 31, 2022	10-K	2024-03-14
Q4 2021	-$180M	$1.71M	+$71.1M		Oct 1, 2021	Dec 31, 2021	10-K	2024-03-14
Q3 2021	-$251M	-$77.7M	-$9.63M	-14.2%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-02
Q2 2021	-$242M	-$71M	-$7.87M	-12.5%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$234M	-$33.2M	+$24.5M	+42.4%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-04
Q4 2020	-$258M	-$69.4M	-$4.79M	-7.41%	Oct 1, 2020	Dec 31, 2020	10-K/A	2024-03-14
Q3 2020	-$253M	-$68M	-$13M	-23.7%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	-$240M	-$63.2M	-$17.2M	-37.4%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-04
Q1 2020	-$223M	-$57.7M	-$21.2M	-58.2%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-05
Q4 2019	-$202M	-$64.6M	-$31.5M	-95.4%	Oct 1, 2019	Dec 31, 2019	10-K	2020-02-27
Q3 2019	-$170M	-$55M	-$32.8M	-148%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-04
Q2 2019	-$138M	-$46M	+$89.1M	+66%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-05
Q1 2019	-$227M	-$36.5M	-$33.9M	-1304%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-06
Q4 2018	-$193M	-$33M			Oct 1, 2018	Dec 31, 2018	10-K	2020-02-27
Q3 2018		-$22.2M			Jul 1, 2018	Sep 30, 2018	10-K	2020-02-27
Q2 2018		-$135M			Apr 1, 2018	Jun 30, 2018	10-K	2020-02-27
Q1 2018		-$2.6M			Jan 1, 2018	Mar 31, 2018	10-K	2020-02-27

* An asterisk sign (*) next to the value indicates that the value is likely invalid.